Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus
(1996) In Lupus 5(6). p.598-601- Abstract
Inherited resistance to activated protein C (APC resistance) is an important risk factor of venous thrombosis. It is caused by a point mutation in the gene coding for coagulation factor V, called FV:Q506. Arterio-venous thrombosis is a common and serious medical problem in patients with systemic lupus erythematosus (SLE). We studied the prevalence of the factor V mutation associated with APC resistance and IgG anticardiolipin antibodies (aCLs) in an epidemiological cohort of 78 Swedish SLE patients, to determine their roles as risk factors for thrombosis. In addition, a detailed evaluation of the clinical manifestations in these patients was performed. Totally, 19 (24%) of the 78 SLE patients had thrombosis, 11 (14%) had venous... (More)
Inherited resistance to activated protein C (APC resistance) is an important risk factor of venous thrombosis. It is caused by a point mutation in the gene coding for coagulation factor V, called FV:Q506. Arterio-venous thrombosis is a common and serious medical problem in patients with systemic lupus erythematosus (SLE). We studied the prevalence of the factor V mutation associated with APC resistance and IgG anticardiolipin antibodies (aCLs) in an epidemiological cohort of 78 Swedish SLE patients, to determine their roles as risk factors for thrombosis. In addition, a detailed evaluation of the clinical manifestations in these patients was performed. Totally, 19 (24%) of the 78 SLE patients had thrombosis, 11 (14%) had venous thrombosis and 8 (10%) had a cerebral infarction caused by occlusion of cerebral vessels. Twenty-six (33%) SLE patients were aCL positive and 8 (10%) were heterozygous for the factor V mutation. Only one of the patients with venous thrombosis and one of the patients with cerebral thrombosis had the FV:Q506 mutation, whereas 3 patients with venous thrombosis and 5 patients with cerebral infarction were aCL positive. Eleven of 19 patients with heart valve disease were aCL positive, a statistically significant association (P = 0.01). In conclusion, we found no statistically significant association between venous thrombosis and FV:Q506 mutation or venous thrombosis and aCL positivity. There was, however, an association between heart valve disease and aCL positivity.
(Less)
- author
- Bengtsson, A
; Zöller, Bengt
LU
; Garcia de Frutos, Pablo LU ; Dahlbäck, Björn LU and Sturfelt, Gunnar LU
- organization
- publishing date
- 1996-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Anticardiolipin, Child, Factor V, Female, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Point Mutation, Thrombosis, Journal Article, Research Support, Non-U.S. Gov't
- in
- Lupus
- volume
- 5
- issue
- 6
- pages
- 4 pages
- publisher
- SAGE Publications
- external identifiers
-
- scopus:0030300003
- pmid:9116703
- ISSN
- 0961-2033
- DOI
- 10.1177/096120339600500607
- language
- English
- LU publication?
- yes
- id
- c25cfbae-1015-4073-9758-64ec2d3d318c
- date added to LUP
- 2017-10-19 16:38:22
- date last changed
- 2024-08-05 06:55:32
@article{c25cfbae-1015-4073-9758-64ec2d3d318c, abstract = {{<p>Inherited resistance to activated protein C (APC resistance) is an important risk factor of venous thrombosis. It is caused by a point mutation in the gene coding for coagulation factor V, called FV:Q506. Arterio-venous thrombosis is a common and serious medical problem in patients with systemic lupus erythematosus (SLE). We studied the prevalence of the factor V mutation associated with APC resistance and IgG anticardiolipin antibodies (aCLs) in an epidemiological cohort of 78 Swedish SLE patients, to determine their roles as risk factors for thrombosis. In addition, a detailed evaluation of the clinical manifestations in these patients was performed. Totally, 19 (24%) of the 78 SLE patients had thrombosis, 11 (14%) had venous thrombosis and 8 (10%) had a cerebral infarction caused by occlusion of cerebral vessels. Twenty-six (33%) SLE patients were aCL positive and 8 (10%) were heterozygous for the factor V mutation. Only one of the patients with venous thrombosis and one of the patients with cerebral thrombosis had the FV:Q506 mutation, whereas 3 patients with venous thrombosis and 5 patients with cerebral infarction were aCL positive. Eleven of 19 patients with heart valve disease were aCL positive, a statistically significant association (P = 0.01). In conclusion, we found no statistically significant association between venous thrombosis and FV:Q506 mutation or venous thrombosis and aCL positivity. There was, however, an association between heart valve disease and aCL positivity.</p>}}, author = {{Bengtsson, A and Zöller, Bengt and Garcia de Frutos, Pablo and Dahlbäck, Björn and Sturfelt, Gunnar}}, issn = {{0961-2033}}, keywords = {{Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Anticardiolipin; Child; Factor V; Female; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Point Mutation; Thrombosis; Journal Article; Research Support, Non-U.S. Gov't}}, language = {{eng}}, number = {{6}}, pages = {{598--601}}, publisher = {{SAGE Publications}}, series = {{Lupus}}, title = {{Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus}}, url = {{http://dx.doi.org/10.1177/096120339600500607}}, doi = {{10.1177/096120339600500607}}, volume = {{5}}, year = {{1996}}, }